Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-52.22%
operating margin TTM
-50.77%
revenue TTM
2.31 Million
revenue per share TTM
1.55$
valuation ratios | |
|---|---|
| pe ratio | -0.55 |
| peg ratio | -0.01 |
| price to book ratio | 0.42 |
| price to sales ratio | 0.31 |
| enterprise value multiple | -4.89 |
| price fair value | 0.42 |
profitability ratios | |
|---|---|
| gross profit margin | 96.52% |
| operating profit margin | -50.77% |
| pretax profit margin | -52.22% |
| net profit margin | -52.22% |
| return on assets | -30.55% |
| return on equity | -121.73% |
| return on capital employed | -72.9% |
liquidity ratio | |
|---|---|
| current ratio | 1.66 |
| quick ratio | 1.62 |
| cash ratio | 1.31 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 455.65 |
| operating cycle | 541.85 |
| days of payables outstanding | 2,396.80 |
| cash conversion cycle | -1,854.96 |
| receivables turnover | 4.23 |
| payables turnover | 0.15 |
| inventory turnover | 0.80 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | -10.38 |
| cash flow to debt ratio | -34.01 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.90 |
| cash per share | 9.71 |
| operating cash flow per share | -3.90 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -34.01 |
| short term coverage ratios | -91.69 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Evoke Pharma, Inc. (NASDAQ:EVOK) reported earnings?
Evoke Pharma, Inc. (EVOK) published its most recent earnings results on 07-11-2024.
What is Evoke Pharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Evoke Pharma, Inc. (NASDAQ:EVOK)'s trailing twelve months ROE is -121.73%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Evoke Pharma, Inc. (EVOK) currently has a ROA of -30.55%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did EVOK's net profit margin stand at?
EVOK reported a profit margin of -52.22% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is EVOK's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.66 in the most recent quarter. The quick ratio stood at 1.62, with a Debt/Eq ratio of 0.02.